Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running|
F. Hoffmann-La Roche Ltd /
Roche ranked the most sustainable healthcare company in the Dow Jones
Sustainability Indices for the tenth year running
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Sustainability is an integral part of Roche's business strategy
* The company performed particularly well in Marketing Practices,
Environmental and Social Reporting and Health Outcome Contribution
Basel, 13 September 2018 - For the tenth consecutive year, Roche (SIX: RO, ROG;
OTCQX: RHHBY) has been recognised as the most sustainable company in the
Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is
based on an in-depth analysis of economic, social and environmental performance.
The DJSI family of indices serves as a benchmark for investors who integrate
sustainability considerations into their portfolios.
Roche has maintained its leadership through its excellent sustainability
strategy, which is fully embedded in the company's business and culture.
"We are proud of being recognised once again for our sustainability efforts,"
says Roche CEO Severin Schwan. "Our most important contribution to society is
the development of medicines and diagnostics that significantly improve people's
lives. Open and constructive dialogue with other companies, universities,
doctors and patients plays an essential role here in understanding the needs of
our partners in the healthcare sector and enabling us to work together to
develop more targeted medical solutions faster."
One example is Roche's partnership with the Michael J. Fox Foundation for
Parkinson's Research (MJFF). Since 2010, Roche has been actively supporting the
Parkinson's Progression Marker Initiative (PPMI) as part of a collaboration
between companies, non-profit organisations and private individuals. Through
this partnership, Roche will soon start to offer study participants access to
its digital biomarker platform, which monitors symptoms of disease progression.
The anonymised data collected by the technology will be published by the PPMI
publicly on a regular basis, for the whole research community - including
Roche's competitors - to access. The hope is that by doing this, we will be able
to better investigate disease progression, speed up clinical development and
improve the treatment of Parkinson's disease.
By helping to accelerate clinical studies and get urgently needed treatments to
patients faster, partnerships like this one are essential to the advancement of
Sustainability at Roche
For over 120 years, sustainability has been an integral part of Roche's
business. Roche follows a holistic approach when managing sustainability: In
addition to improving access to products, the company's strategy also focuses on
achieving continuous progress in areas such as social responsibility,
environmental protection, supply chain sustainability, people attraction and
Roche makes its biggest contribution to society by improving healthcare
provision. It does so by developing the best diagnostic tests and medicines
capable of meeting some of the world's most pressing medical needs.
Roche is aware that this cannot be done alone. The company knows that the key to
creating sustainable value and growth lies in partnering with stakeholders and
engaging in open, constructive dialogue. By doing so, Roche not only generates
value for society through its medicines and technology but achieves sustainable
economic growth for itself.
Examples of our activities in sustainability areas can be found here:
About the Dow Jones Sustainability Indices (DJSI)
This global ranking is published annually by the S&P Dow Jones Indices and
RobecoSAM and measures the performance of the world's sustainability leaders.
RobecoSAM invites over 3,400 publicly traded companies to participate. Companies
are selected for the indices according to a systematic Corporate Sustainability
Assessment (CSA) performed by RobecoSAM. Only firms that lead their industries
based on this assessment are included in the indices. This is determined by a
comprehensive assessment of long-term economic, environmental and social
criteria that take account of general as well as industry-specific
Roche is a global pioneer in pharmaceuticals and diagnostics focused on
advancing science to improve people's lives. The combined strengths of
pharmaceuticals and diagnostics under one roof have made Roche the leader in
personalised healthcare - a strategy that aims to fit the right treatment to
each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated
medicines in oncology, immunology, infectious diseases, ophthalmology and
diseases of the central nervous system. Roche is also the world leader in in
vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in
Founded in 1896, Roche continues to search for better ways to prevent, diagnose
and treat diseases and make a sustainable contribution to society. The company
also aims to improve patient access to medical innovations by working with all
relevant stakeholders. Thirty medicines developed by Roche are included in the
World Health Organization Model Lists of Essential Medicines, among them life-
saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth
consecutive year, Roche has been recognised as the most sustainable company in
the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100
countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche
invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion.
Genentech, in the United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: email@example.com
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Simone Oeschger
- Anja von Treskow
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: F. Hoffmann-La Roche Ltd via GlobeNewswire
durchschnittliche Punktzahl: 0|